Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
The primary study was the ability of gallium [68Ga] NOTA-DNA multivalent SGC8 injection to provide tumor-specific imaging of bladder tumor patients of different genders, with a compliance rate of more than 80% when compared to the gold standard TUR pathology.
Sponsor:
RenJi Hospital
Contacts:
Peifeng Liu2775@renji.com
86 13512116782
Government Study Link:
NCT06763354 - Click here to see study onClinicalTrials.gov
Help us improve your experience